Market Cap 9.54B
Revenue (ttm) 738.26M
Net Income (ttm) 48.89M
EPS (ttm) N/A
PE Ratio 84.69
Forward PE 80.96
Profit Margin 6.62%
Debt to Equity Ratio 0.00
Volume 1,326,063
Avg Vol 1,128,132
Day's Range N/A - N/A
Shares Out 56.44M
Stochastic %K 75%
Beta 1.03
Analysts Strong Sell
Price Target $184.35

Company Profile

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sampl...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 781 250 0111
Fax: 781 250 0115
Address:
Building 1, Suite 100 41 Seyon Street, Waltham, United States
StocktwitsNews
StocktwitsNews Aug. 19 at 6:21 PM
These Two Biotech Stocks Recorded Fresh Milestones Today – What’s Driving Today’s Gains? $AMGN $RGEN https://stocktwits.com/news/equity/markets/amgn-rgen-stocks-hit-52-week-highs-today/cZYdYDVRJlm
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 19 at 5:49 PM
TEM, BNTX, MRVI, RGEN, NVAX Stock Rallies As Moderna-Merck Cancer Vaccine Clears Late-stage Trial $TEM $NVAX $BNTX $MRVI $RGEN https://stocktwits.com/news/equity/markets/tem-bntx-mrvi-rgen-nvax-stock-rallies-as-moderna-merck-cancer-vaccine-clears-late-stage-trial/cZYdob1RJlk
0 · Reply
notreload_ai
notreload_ai Aug. 19 at 2:12 PM
Wells Fargo & Stifel say Moderna-Merck Phase 3 cancer vaccine data could benefit $RGEN, $DHR, $TMO & $MRVI . https://notreload.xyz/xy/moderna-merck-cancer-vaccine-boosts-biotech-suppliers/
0 · Reply
Do_The_Math
Do_The_Math Aug. 15 at 12:02 AM
$RGEN $TMO etc charts look ripe + frontier AI labs are going to focus on biotech to win over the court of public opinion on AI. AI will speed up molecule discovery and drilling in on what molecules/targets to test but at the end of the day you still need to test, manufacture, etc. which requires real assets that these companies produce. Light position for now, just an idea but will take time to build conviction in it. Next market drawdown think worth while to see how these act. Already saw $DHR whiff on bio processing and fully retrace the move, that’s very valuable info in my opinion. Think some smarter people saw this idea months ago but think it’s very early if it comes to fruition.
1 · Reply
STACKD0E
STACKD0E Aug. 11 at 7:48 PM
$POLA $RGEN 🙃✨️
0 · Reply
UCIdidmyDD
UCIdidmyDD Aug. 8 at 5:41 PM
$OKLO $RGEN $AXON i sense big moves incoming these 3 are special. but otherwise unrelated
0 · Reply
sDinvestments1
sDinvestments1 Aug. 5 at 7:49 PM
$RGEN When the $BLFS deal closes Repligen’s annual rev’s will essentially likely top $1 billion. Expect $RGEN to continue to climb as a highly respected and integrated cell therapy fixture that is purposing its capital incredibly well!
1 · Reply
Estimize
Estimize Aug. 5 at 10:01 AM
Wall St is expecting 0.46 EPS for $RGEN Q3 [Reporting 11/03 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co
0 · Reply
vjtweet
vjtweet Aug. 4 at 2:22 AM
$RGEN Noisy but 200 should be possible in few months. Has position.
0 · Reply
sDinvestments1
sDinvestments1 Jul. 31 at 7:34 PM
$NWBO $RGEN $CYRX $BLFS Some DD and info on the companies involved in the consumables, shipping, and cryo portions of cell therapies and NWBO’s own dcvax l processing. This started with the videos and pics that Braelyn’s mother shared of her recently traveling to the UK to get her first round of dcvax administered. I ran analysis on the shipper as i have actually seen this shipper before in two different airports. There is an advent link between CYRX and NWBO as well. I would very much like to own a pile of RGEN for a long long hold if we see a decent stockprice in the days following initial MHRA approval. @808right @Surforever @Thousandaire5 @IMA_FNG @TheWayISeeIt https://chatgpt.com/s/t_6a6cf55e50348191ba5f3ce43ecf5061
4 · Reply
Latest News on RGEN
Repligen price target raised to $175 from $165 at JPMorgan

2026-07-29T12:03:01.000Z - 21 days ago

Repligen price target raised to $175 from $165 at JPMorgan


Repligen rises 15.4%

2026-07-28T16:05:46.000Z - 22 days ago

Repligen rises 15.4%


Repligen rises 16.2%

2026-07-28T14:05:42.000Z - 22 days ago

Repligen rises 16.2%


Repligen Earnings Call Transcript: Q2 2026

Jul 28, 2026, 8:00 AM EDT - 22 days ago

Repligen Earnings Call Transcript: Q2 2026


Repligen Earnings release: Q2 2026

Jul 28, 2026, 8:00 AM EDT - 22 days ago

Repligen Earnings release: Q2 2026


Repligen Slides: Q2 2026

Jul 28, 2026, 8:00 AM EDT - 22 days ago

Repligen Slides: Q2 2026


Repligen Quarterly report: Q2 2026

Jul 28, 2026, 8:00 AM EDT - 22 days ago

Repligen Quarterly report: Q2 2026


Repligen reports Q2 adjusted EPS 54c, consensus 45c

2026-07-28T11:12:08.000Z - 22 days ago

Repligen reports Q2 adjusted EPS 54c, consensus 45c


Repligen Transcript: M&A announcement

Jul 22, 2026, 8:30 AM EDT - 4 weeks ago

Repligen Transcript: M&A announcement


Repligen Press release: M&A announcement

Jul 22, 2026, 8:30 AM EDT - 4 weeks ago

Repligen Press release: M&A announcement


Repligen Slides: M&A announcement

Jul 22, 2026, 8:30 AM EDT - 4 weeks ago

Repligen Slides: M&A announcement


Repligen to Report Second Quarter 2026 Financial Results

Jul 15, 2026, 7:30 AM EDT - 5 weeks ago

Repligen to Report Second Quarter 2026 Financial Results


Repligen upgraded to Buy from Hold at Benchmark

2026-07-07T10:35:37.000Z - 6 weeks ago

Repligen upgraded to Buy from Hold at Benchmark


Repligen price target lowered to $150 from $170 at HSBC

2026-06-03T09:38:54.000Z - 2 months ago

Repligen price target lowered to $150 from $170 at HSBC


Repligen assumed with an Outperform at Wolfe Research

2026-06-01T20:43:43.000Z - 2 months ago

Repligen assumed with an Outperform at Wolfe Research


Repligen resumed with an Outperform at RBC Capital

2026-05-14T20:55:47.000Z - 3 months ago

Repligen resumed with an Outperform at RBC Capital


Repligen Transcript: AGM 2026

May 14, 2026, 8:00 AM EDT - 3 months ago

Repligen Transcript: AGM 2026


Repligen price target raised to $160 from $145 at Barclays

2026-05-07T10:15:25.000Z - 3 months ago

Repligen price target raised to $160 from $145 at Barclays


Repligen Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

Repligen Earnings Call Transcript: Q1 2026


Repligen Earnings release: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

Repligen Earnings release: Q1 2026


Repligen Slides: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

Repligen Slides: Q1 2026


Repligen Quarterly report: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

Repligen Quarterly report: Q1 2026


Repligen Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Repligen Proxy statement: Proxy filing


Repligen to Report First Quarter 2026 Financial Results

Apr 22, 2026, 7:30 AM EDT - 4 months ago

Repligen to Report First Quarter 2026 Financial Results


Repligen Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 4 months ago

Repligen Proxy statement: Proxy filing


Repligen Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 4 months ago

Repligen Proxy statement: Proxy filing


Repligen Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 11:20 AM EDT - 5 months ago

Repligen Transcript: Leerink Global Healthcare Conference 2026


Repligen Slides: Investor presentation

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Repligen Slides: Investor presentation


Repligen Earnings Call Transcript: Q4 2025

Feb 24, 2026, 8:30 AM EST - 6 months ago

Repligen Earnings Call Transcript: Q4 2025


Repligen Annual report: Q4 2025

Feb 24, 2026, 8:30 AM EST - 6 months ago

Repligen Annual report: Q4 2025


Repligen Earnings release: Q4 2025

Feb 24, 2026, 8:30 AM EST - 6 months ago

Repligen Earnings release: Q4 2025


Repligen Annual report: Q4 2025

Feb 24, 2026, 8:30 AM EST - 6 months ago

Repligen Annual report: Q4 2025


Repligen Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 5:15 PM EST - 7 months ago

Repligen Slides: 44th Annual J.P. Morgan Healthcare Conference


Repligen Transcript: Wolfe Research Healthcare Conference 2025

Nov 18, 2025, 12:40 PM EST - 9 months ago

Repligen Transcript: Wolfe Research Healthcare Conference 2025


Repligen Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 8:30 AM EST - 9 months ago

Repligen Transcript: Jefferies London Healthcare Conference 2025


Repligen Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 10:00 AM EST - 10 months ago

Repligen Transcript: Stifel 2025 Healthcare Conference


Repligen Transcript: UBS Global Healthcare Conference 2025

Nov 10, 2025, 11:00 AM EST - 10 months ago

Repligen Transcript: UBS Global Healthcare Conference 2025


Repligen Slides: Investor Presentation

Nov 9, 2025, 6:00 PM EST - 10 months ago

Repligen Slides: Investor Presentation


Repligen Earnings Call Transcript: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 10 months ago

Repligen Earnings Call Transcript: Q3 2025


Repligen Quarterly report: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 10 months ago

Repligen Quarterly report: Q3 2025


Repligen Earnings release: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 10 months ago

Repligen Earnings release: Q3 2025


Repligen to Report Third Quarter 2025 Financial Results

Oct 15, 2025, 7:30 AM EDT - 11 months ago

Repligen to Report Third Quarter 2025 Financial Results


Repligen Earnings Call Transcript: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 1 year ago

Repligen Earnings Call Transcript: Q2 2025


Repligen Quarterly report: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 1 year ago

Repligen Quarterly report: Q2 2025


Repligen Earnings release: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 1 year ago

Repligen Earnings release: Q2 2025


Repligen to Report Second Quarter 2025 Financial Results

Jul 17, 2025, 7:30 AM EDT - 1 year ago

Repligen to Report Second Quarter 2025 Financial Results


Repligen Slides: Investor Presentation

Jun 24, 2025, 9:00 AM EDT - 1 year ago

Repligen Slides: Investor Presentation


Repligen Earnings Call Transcript: Q1 2025

Apr 29, 2025, 8:30 AM EDT - 1 year ago

Repligen Earnings Call Transcript: Q1 2025


Repligen Quarterly report: Q1 2025

Apr 29, 2025, 8:30 AM EDT - 1 year ago

Repligen Quarterly report: Q1 2025


Repligen Earnings release: Q1 2025

Apr 29, 2025, 8:30 AM EDT - 1 year ago

Repligen Earnings release: Q1 2025


Repligen Reports First Quarter 2025 Financial Results

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Repligen Reports First Quarter 2025 Financial Results


Repligen Proxy statement: Proxy Filing

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Repligen Proxy statement: Proxy Filing


Repligen Proxy statement: Proxy Filing

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Repligen Proxy statement: Proxy Filing


Repligen Proxy statement: Proxy Filing

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Repligen Proxy statement: Proxy Filing


Repligen Earnings Call Transcript: Q4 2024

Feb 20, 2025, 8:30 AM EST - 1 year ago

Repligen Earnings Call Transcript: Q4 2024


Repligen Annual report: Q4 2024

Feb 20, 2025, 8:30 AM EST - 1 year ago

Repligen Annual report: Q4 2024


Repligen Earnings release: Q4 2024

Feb 20, 2025, 8:30 AM EST - 1 year ago

Repligen Earnings release: Q4 2024


Repligen Launches the CTech™ SoloVPE® PLUS System

Jan 6, 2025, 7:30 AM EST - 1 year ago

Repligen Launches the CTech™ SoloVPE® PLUS System


Repligen Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 12:40 PM EST - 1 year ago

Repligen Transcript: Stifel 2024 Healthcare Conference


Repligen Transcript: UBS Global Healthcare Conference 2024

Nov 14, 2024, 10:15 AM EST - 1 year ago

Repligen Transcript: UBS Global Healthcare Conference 2024


Repligen Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Repligen Earnings Call Transcript: Q3 2024


Repligen Quarterly report: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Repligen Quarterly report: Q3 2024


Repligen Earnings release: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Repligen Earnings release: Q3 2024


Repligen Transcript: 2024 Wells Fargo Healthcare Conference

Sep 6, 2024, 8:45 AM EDT - 2 years ago

Repligen Transcript: 2024 Wells Fargo Healthcare Conference


Repligen Earnings Call Transcript: Q2 2024

Jul 30, 2024, 8:30 AM EDT - 2 years ago

Repligen Earnings Call Transcript: Q2 2024


Repligen Quarterly report: Q2 2024

Jul 30, 2024, 8:30 AM EDT - 2 years ago

Repligen Quarterly report: Q2 2024


Repligen Earnings release: Q2 2024

Jul 30, 2024, 8:30 AM EDT - 2 years ago

Repligen Earnings release: Q2 2024


Repligen Reports Second Quarter 2024 Financial Results

Jul 30, 2024, 7:30 AM EDT - 2 years ago

Repligen Reports Second Quarter 2024 Financial Results


Repligen to Report Second Quarter 2024 Financial Results

Jul 16, 2024, 7:30 AM EDT - 2 years ago

Repligen to Report Second Quarter 2024 Financial Results


Repligen Announces CEO Transition Plan

Jun 13, 2024, 7:00 AM EDT - 2 years ago

Repligen Announces CEO Transition Plan


Repligen Transcript: Jefferies Global Healthcare Conference

Jun 6, 2024, 11:30 AM EDT - 2 years ago

Repligen Transcript: Jefferies Global Healthcare Conference


Repligen Proxy statement: Proxy Filing

May 3, 2024, 8:00 AM EDT - 2 years ago

Repligen Proxy statement: Proxy Filing


Repligen Earnings Call Transcript: Q1 2024

May 1, 2024, 8:30 AM EDT - 2 years ago

Repligen Earnings Call Transcript: Q1 2024


Repligen Quarterly report: Q1 2024

May 1, 2024, 8:30 AM EDT - 2 years ago

Repligen Quarterly report: Q1 2024


Repligen Earnings release: Q1 2024

May 1, 2024, 8:30 AM EDT - 2 years ago

Repligen Earnings release: Q1 2024


Repligen Reports First Quarter 2024 Financial Results

May 1, 2024, 7:30 AM EDT - 2 years ago

Repligen Reports First Quarter 2024 Financial Results


Repligen to Report First Quarter 2024 Financial Results

Apr 17, 2024, 7:30 AM EDT - 2 years ago

Repligen to Report First Quarter 2024 Financial Results


Repligen Proxy statement: Proxy Filing

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Repligen Proxy statement: Proxy Filing


Repligen Proxy statement: Proxy Filing

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Repligen Proxy statement: Proxy Filing


Repligen Appoints Maggie A. Pax to Board of Directors

Mar 19, 2024, 7:30 AM EDT - 2 years ago

Repligen Appoints Maggie A. Pax to Board of Directors


StocktwitsNews
StocktwitsNews Aug. 19 at 6:21 PM
These Two Biotech Stocks Recorded Fresh Milestones Today – What’s Driving Today’s Gains? $AMGN $RGEN https://stocktwits.com/news/equity/markets/amgn-rgen-stocks-hit-52-week-highs-today/cZYdYDVRJlm
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 19 at 5:49 PM
TEM, BNTX, MRVI, RGEN, NVAX Stock Rallies As Moderna-Merck Cancer Vaccine Clears Late-stage Trial $TEM $NVAX $BNTX $MRVI $RGEN https://stocktwits.com/news/equity/markets/tem-bntx-mrvi-rgen-nvax-stock-rallies-as-moderna-merck-cancer-vaccine-clears-late-stage-trial/cZYdob1RJlk
0 · Reply
notreload_ai
notreload_ai Aug. 19 at 2:12 PM
Wells Fargo & Stifel say Moderna-Merck Phase 3 cancer vaccine data could benefit $RGEN, $DHR, $TMO & $MRVI . https://notreload.xyz/xy/moderna-merck-cancer-vaccine-boosts-biotech-suppliers/
0 · Reply
Do_The_Math
Do_The_Math Aug. 15 at 12:02 AM
$RGEN $TMO etc charts look ripe + frontier AI labs are going to focus on biotech to win over the court of public opinion on AI. AI will speed up molecule discovery and drilling in on what molecules/targets to test but at the end of the day you still need to test, manufacture, etc. which requires real assets that these companies produce. Light position for now, just an idea but will take time to build conviction in it. Next market drawdown think worth while to see how these act. Already saw $DHR whiff on bio processing and fully retrace the move, that’s very valuable info in my opinion. Think some smarter people saw this idea months ago but think it’s very early if it comes to fruition.
1 · Reply
STACKD0E
STACKD0E Aug. 11 at 7:48 PM
$POLA $RGEN 🙃✨️
0 · Reply
UCIdidmyDD
UCIdidmyDD Aug. 8 at 5:41 PM
$OKLO $RGEN $AXON i sense big moves incoming these 3 are special. but otherwise unrelated
0 · Reply
sDinvestments1
sDinvestments1 Aug. 5 at 7:49 PM
$RGEN When the $BLFS deal closes Repligen’s annual rev’s will essentially likely top $1 billion. Expect $RGEN to continue to climb as a highly respected and integrated cell therapy fixture that is purposing its capital incredibly well!
1 · Reply
Estimize
Estimize Aug. 5 at 10:01 AM
Wall St is expecting 0.46 EPS for $RGEN Q3 [Reporting 11/03 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co
0 · Reply
vjtweet
vjtweet Aug. 4 at 2:22 AM
$RGEN Noisy but 200 should be possible in few months. Has position.
0 · Reply
sDinvestments1
sDinvestments1 Jul. 31 at 7:34 PM
$NWBO $RGEN $CYRX $BLFS Some DD and info on the companies involved in the consumables, shipping, and cryo portions of cell therapies and NWBO’s own dcvax l processing. This started with the videos and pics that Braelyn’s mother shared of her recently traveling to the UK to get her first round of dcvax administered. I ran analysis on the shipper as i have actually seen this shipper before in two different airports. There is an advent link between CYRX and NWBO as well. I would very much like to own a pile of RGEN for a long long hold if we see a decent stockprice in the days following initial MHRA approval. @808right @Surforever @Thousandaire5 @IMA_FNG @TheWayISeeIt https://chatgpt.com/s/t_6a6cf55e50348191ba5f3ce43ecf5061
4 · Reply
Spicy_Trade
Spicy_Trade Jul. 28 at 11:51 PM
Repligen Corporation ( $RGEN ) SpicyTrade - Daily Stock Analysis https://youtu.be/1reNojBQD8A?si=HfR2SAW_0GgOzHan
0 · Reply
flychicken1991
flychicken1991 Jul. 28 at 7:15 PM
$RGEN Positive (70%): shares face upward price pressure because a stronger full-year outlook can prompt analysts to increase forward revenue and earnings estimates; the reported 13.8% gain indicates that repricing was already substantial. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/f9b45b434f05fbeb?utm_source=stocktwits&utm_medium=story_url
0 · Reply
notreload_ai
notreload_ai Jul. 28 at 4:15 PM
$RGEN posts $204M Q2 revenue (+12%), adjusted EPS of $0.54 beating estimates. Raises FY26 organic growth to 10.5%-13.5% and EPS to $2.03-$2.09. https://notreload.xyz/xy/repligen-beats-q2-estimates-raises-2026-guidance/
0 · Reply
STACKD0E
STACKD0E Jul. 28 at 3:47 PM
0 · Reply
EarningsInsider
EarningsInsider Jul. 28 at 1:16 PM
https://www.marketbeat.com/earnings/reports/2026-7-28-repligen-co-stock/ $RGEN Repligen Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Jul. 28 at 11:18 AM
$RGEN Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.09 down -65.38% YoY • Reported revenue of $204.13M up 11.93% YoY • Repligen Corporation raised its full year 2026 organic revenue growth guidance to 10.5%-13.5% and adjusted earnings per share guidance to $2.03-$2.09, based on expectations for the company's existing business.
0 · Reply
notreload_ai
notreload_ai Jul. 22 at 10:54 AM
$RGEN to acquire $BLFS in a $1.5B cash-and-stock deal to strengthen its position in the fast-growing cell and gene therapy market. Expected to close Q4 2026. https://notreload.xyz/xy/repligen-acquires-biolife-solutions-for-1-5b/
0 · Reply
UCIdidmyDD
UCIdidmyDD Jun. 27 at 6:40 PM
$RGEN this a Buffett, Lynch, anyone with a brain stock. i mean $LWAY dominates their market but its just not the comparison that you wanna do. nothing wrong with lifeway but its more proprietary to sybthesize protein A
0 · Reply
UCIdidmyDD
UCIdidmyDD Jun. 26 at 9:27 PM
$RGEN yeah so i owned this in the 3-4$ range in the 00’s. Herlihy ? was tbe CEO. thats when the run began. anywho, a bit older but back in today for a starter.
0 · Reply
vjtweet
vjtweet Jun. 4 at 3:28 PM
$RGEN Opened new long position.
1 · Reply
SuperGreenToday
SuperGreenToday May. 21 at 5:15 PM
$RGEN Share Price: $112.18 Contract Selected: Nov 20, 2026 $115 Calls Buy Zone: $12.92 – $15.96 Target Zone: $21.68 – $26.50 Potential Upside: 58% ROI Time to Expiration: 182 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Estimize
Estimize May. 21 at 11:00 AM
Wall St is expecting 0.45 EPS for $RGEN Q2 [Reporting 08/04 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co
0 · Reply